Valproic acid reduces muscle susceptibility to contraction‐induced functional loss but increases weakness in two murine models of Duchenne muscular dystrophy
Clinical and Experimental Pharmacology and Physiology · 2023-09 · 50 (9) · 749-756
DOI: 10.1111/1440-1681.13804 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Pharmacology and Physiology, online erschienen am 29.06.2023. Verfasst von Dylan Moutachi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Centre de Recherche en Myologie, UMRS974, Inserm, Association Institut de Myologie, Sorbonne Université, Paris, France. Hauptthemen laut MEDLINE: Muscular Dystrophy, Duchenne. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Skeletal muscles in animal models of Duchenne muscular dystrophy (DMD) are more susceptible to contraction‐induced functional loss, which is not related to fatigue. Valproic acid (VPA) reportedly improves serological and histological markers of damage in dystrophin‐deficient murine muscle. Here, we tested whether VPA would reduce the susceptibility to contraction‐induced functional loss in two murine DMD models. Adult female mdx (mild) and D2‐mdx (severe) DMD murine models were administered VPA (240 mg/kg) or saline for 7 days. Some VPA‐treated mdx mice also performed voluntary running in a wheel, which is known to reduce the susceptibility to contraction‐induced functional loss; that is, isometric force drop following eccentric contractions. In situ muscle function was assessed before, during and after eccentric contractions. Muscle utrophin and desmin expression were also evaluated using immunoblotting. Interestingly, VPA reduced the isometric force drop following eccentric contractions in both murine models, without change in the relative eccentric maximal force and in the expression of utrophin and desmin. VPA for 7 days combined with voluntary running had no additive effect compared to VPA alone. Furthermore, VPA reduced the absolute isometric maximal force before eccentric contractions in both murine models. The results of our study indicated that VPA in both murine DMD models reduced the susceptibility to contraction‐induced functional loss but increased muscle weakness.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre de Recherche en Myologie, UMRS974, Inserm, Association Institut de Myologie, Sorbonne Université, Paris, France.
- Institut de Biologie Paris-Seine, UMR CNRS 8256, Inserm ERL U1164, Biological Adaptation and Ageing, Sorbonne Université, Paris, France.
- Université Paris Cité, Paris, France.
ORCID-Profile: Arnaud Ferry
Zitieren
APA
Moutachi, D., Lemaitre, M., Delacroix, C., Agbulut, O., Furling, D., & Ferry, A. (2023). Valproic acid reduces muscle susceptibility to contraction‐induced functional loss but increases weakness in two murine models of Duchenne muscular dystrophy. Clinical and Experimental Pharmacology and Physiology, 50(9), 749-756. https://doi.org/10.1111/1440-1681.13804
Vancouver
Moutachi D, Lemaitre M, Delacroix C, Agbulut O, Furling D, Ferry A. Valproic acid reduces muscle susceptibility to contraction‐induced functional loss but increases weakness in two murine models of Duchenne muscular dystrophy. Clinical and Experimental Pharmacology and Physiology. 2023;50(9):749-756. doi:10.1111/1440-1681.13804
BibTeX
@article{Moutachi2023,
author = {Moutachi, Dylan and Lemaitre, Mégane and Delacroix, Clément and Agbulut, Onnik and Furling, Denis and Ferry, Arnaud},
title = {Valproic acid reduces muscle susceptibility to contraction‐induced functional loss but increases weakness in two murine models of Duchenne muscular dystrophy},
journal = {Clinical and Experimental Pharmacology and Physiology},
year = {2023},
volume = {50},
number = {9},
pages = {749--756},
doi = {10.1111/1440-1681.13804}
}
EUVIMED